- Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Active Not Recruiting • Phase III • Oncology • NCT06486441.
- Sacituzumab govitecan improves survival compared to standard treatment in advanced endometrial cancer patients previously treated with chemotherapy and immunotherapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS). Conditions: Endometrial Cancer Interventions: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel Lead Sponsor: Gilead Sciences Planned Enrollment: 640 participants